Glioblastoma Multiforme

Dr. DeVita is Professor of Medicine and Professor of Epidemiology and Public Health at the Yale University School of Medicine in New Haven, CT. He is the former Director of the National Cancer Institute and developed the cure for Hodgkin's Disease and other lymphomas. He is the Director Emeritus at the Yale Cancer Center and has received numerous awards including the Mary and Albert Lasker Prize, the Medal of Honor from the American Cancer Society, the first Pezcoller Award from the European School of Oncology, the Armand Hammer Cancer Prize and the Surgeon General's Exemplary Service Medal. He recently was recognized with the 50th Anniversary Commemorative Award from the Leukemia Society of America and was the recipient of the first Saul Rosenberg Research Award from the Lymphoma Research Foundation of America. Dr. DeVita also served as co-chair of the National Cancer Legislative Advisory Committee for revising the National Cancer Act of 1971. Dr. Rosenberg received his B.A. and M.D. from the Johns Hopkins University, and he received a Ph.D. in biophysics from Harvard University. Following the completion of his surgical residency at the Peter Bent Brigham Hospital in Boston, MA, Dr. Rosenberg became chief of the Surgery Branch at the National Cancer Institute, Bethesda, MD in July 1974, a position he continues to hold now. His research interests have focused on studies of tumor immunology and the development of effective immunotherapies for the treatment of patients with cancer. In the course of his career as a practitioner, teacher, investigator and leader in radiation oncology, Samuel Hellman, M.D., has advanced his specialty in too many ways to count. Although he is perhaps best known for advancing cancer treatment with his groundbreaking clinical research on malignant lymphomas and breast cancer, Dr. Hellman's accomplishments at the institutions he served and with the students he mentored also have transformed and elevated the role of radiation oncology. As a member of numerous external advisory committees, cancer-center boards, and research funding agencies, Dr. Hellman is a powerful advocate for radiology and the radiological sciences.